Vaccinomics and personalized vaccinology

Is science leading us toward a new path of directed vaccine development and discovery?

Gregory A. Poland, Richard B Kennedy, Inna G. Ovsyannikova

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

As is apparent in many fields of science and medicine, the new biology, and particularly new high-throughput genetic sequencing and transcriptomic and epigenetic technologies, are radically altering our understanding and views of science. In this article, we make the case that while mostly ignored thus far in the vaccine field, these changes will revolutionize vaccinology from development to manufacture to administration. Such advances will address a current major barrier in vaccinology-that of empiric vaccine discovery and development, and the subsequent low yield of viable vaccine candidates, particularly for hyper-variable viruses. While our laboratory's data and thinking (and hence also for this paper) has been directed toward viruses and viral vaccines, generalization to other pathogens and disease entities (i.e., anti-cancer vaccines) may be appropriate.

Original languageEnglish (US)
Article numbere1002344
JournalPLoS Pathogens
Volume7
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Vaccines
Viral Vaccines
Viruses
Cancer Vaccines
Epigenomics
Medicine
Technology

ASJC Scopus subject areas

  • Microbiology
  • Parasitology
  • Virology
  • Immunology
  • Genetics
  • Molecular Biology

Cite this

Vaccinomics and personalized vaccinology : Is science leading us toward a new path of directed vaccine development and discovery? / Poland, Gregory A.; Kennedy, Richard B; Ovsyannikova, Inna G.

In: PLoS Pathogens, Vol. 7, No. 12, e1002344, 12.2011.

Research output: Contribution to journalArticle

@article{7afe558fab9d42579f18a68f65a6622f,
title = "Vaccinomics and personalized vaccinology: Is science leading us toward a new path of directed vaccine development and discovery?",
abstract = "As is apparent in many fields of science and medicine, the new biology, and particularly new high-throughput genetic sequencing and transcriptomic and epigenetic technologies, are radically altering our understanding and views of science. In this article, we make the case that while mostly ignored thus far in the vaccine field, these changes will revolutionize vaccinology from development to manufacture to administration. Such advances will address a current major barrier in vaccinology-that of empiric vaccine discovery and development, and the subsequent low yield of viable vaccine candidates, particularly for hyper-variable viruses. While our laboratory's data and thinking (and hence also for this paper) has been directed toward viruses and viral vaccines, generalization to other pathogens and disease entities (i.e., anti-cancer vaccines) may be appropriate.",
author = "Poland, {Gregory A.} and Kennedy, {Richard B} and Ovsyannikova, {Inna G.}",
year = "2011",
month = "12",
doi = "10.1371/journal.ppat.1002344",
language = "English (US)",
volume = "7",
journal = "PLoS Pathogens",
issn = "1553-7366",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Vaccinomics and personalized vaccinology

T2 - Is science leading us toward a new path of directed vaccine development and discovery?

AU - Poland, Gregory A.

AU - Kennedy, Richard B

AU - Ovsyannikova, Inna G.

PY - 2011/12

Y1 - 2011/12

N2 - As is apparent in many fields of science and medicine, the new biology, and particularly new high-throughput genetic sequencing and transcriptomic and epigenetic technologies, are radically altering our understanding and views of science. In this article, we make the case that while mostly ignored thus far in the vaccine field, these changes will revolutionize vaccinology from development to manufacture to administration. Such advances will address a current major barrier in vaccinology-that of empiric vaccine discovery and development, and the subsequent low yield of viable vaccine candidates, particularly for hyper-variable viruses. While our laboratory's data and thinking (and hence also for this paper) has been directed toward viruses and viral vaccines, generalization to other pathogens and disease entities (i.e., anti-cancer vaccines) may be appropriate.

AB - As is apparent in many fields of science and medicine, the new biology, and particularly new high-throughput genetic sequencing and transcriptomic and epigenetic technologies, are radically altering our understanding and views of science. In this article, we make the case that while mostly ignored thus far in the vaccine field, these changes will revolutionize vaccinology from development to manufacture to administration. Such advances will address a current major barrier in vaccinology-that of empiric vaccine discovery and development, and the subsequent low yield of viable vaccine candidates, particularly for hyper-variable viruses. While our laboratory's data and thinking (and hence also for this paper) has been directed toward viruses and viral vaccines, generalization to other pathogens and disease entities (i.e., anti-cancer vaccines) may be appropriate.

UR - http://www.scopus.com/inward/record.url?scp=84855254098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855254098&partnerID=8YFLogxK

U2 - 10.1371/journal.ppat.1002344

DO - 10.1371/journal.ppat.1002344

M3 - Article

VL - 7

JO - PLoS Pathogens

JF - PLoS Pathogens

SN - 1553-7366

IS - 12

M1 - e1002344

ER -